-

$undefined

N/A

(N/A)

Soleno Therapeutics NASDAQ:SLNO Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.

Location: 1235 Radio Rd Ste 110, California, 94065-1315, US | Website: soleno.life | Industry: Surgical and Medical Instrument Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.024B

Cash

291.4M

Avg Qtr Burn

-17.27M

Short % of Float

16.44%

Insider Ownership

2.93%

Institutional Own.

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DCCR (Diazoxide Choline Controlled-Release) (K ATP agonist) Details Prader-Willi syndrome, Genetic disorder Big Mover™ Suspected Mover™ Susp. Mover™	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.